U.S. MARKETS FOR NEUROSTIMULATION PRODUCTS
248 Pages | 61 Exhibits | 2006 Analysis | Forecasts Through 2010
Neurostimulation currently treats several debilitating conditions, including: major treatment-resistant depression, epilepsy, gastroparesis, hearing loss, incontinence, chronic, untreatable pain, Parkinson's disease, essential tremor and dystonia. Emerging and exciting areas of development include the treatment of large-population diseases and disorders, including Alzheimer's disease, blindness, chronic migraines, morbid obesity, obsessive-compulsive disorder, paralysis, sleep apnea, stroke, and severe tinnitus, with the potential to expand to several other applications.
The neurostimulation market is poised for significant growth over the next decade, due to the aging population, growth in age-related neurological and other diseases and disorders, and strong need for effective, alternative therapies. Neurostimulation systems present a hopeful, life-improving (and life-saving) alternative to many patients who do not obtain relief from standard drug and surgical therapy. The market will continue to benefit from technological improvements, limited competition, high profit, high barriers to entry, long-term cost-effectiveness, and the increase in FDA-approved clinical trials for new applications.
In 2005, the total U.S. market for neurostimulation products (including cochlear implants) was estimated at $830 million. This market is expected to grow at a compound annual rate of 17.1%, reaching more than $1.8 billion in 2010, with the potential to double or triple over the next decade.
This dynamic report from Medtech Insight includes analyses of products, technologies, current and forecast markets, competitors, and opportunities. Covered topics in this report include: cochlear implants, cortical stimulators, deep brain stimulators, gastric nerve stimulators, sacral nerve stimulators, spinal cord stimulators, vagus nerve stimulators and emerging technologies. Noninvasive stimulation technologies, such as magnetic stimulation therapy and transcutaneous electrical nerve stimulation (TENS), are also
EXECUTIVE SUMMARY
i. Neurostimulation Products
ii. Types of Implantable Neurostimulators
a. Cortical Stimulators
b. Deep Brain Stimulators
c. Gastric Nerve Stimulators
d. Sacral Nerve Stimulators
e. Spinal Cord Stimulators
f. Vagus Nerve Stimulators
g. Cochlear Implants
iii. Neurostimulation Products Market
iv. Methodology
Exhibit ES-1: 2006, Neurostimulation, Potential Applications
Exhibit ES-2: 2006, Patients Who Have Received Neurostimulation Implants, by Selected Neurologic Condition
Exhibit ES-3: 2006, Selected Neurologic Conditions, Estimated Prevalence and Potential Neurostimulation Patient Population
Exhibit ES-4: 2006, Selected Advantages and Disadvantages of Neurostimulation Therapy
Exhibit ES-5: 2006, Established Neurostimulation Therapies and Leading Competitors
Exhibit ES-6: 2006, Selected Current and Emerging Neurostimulation Systems
Exhibit ES-7: 2006, Selected Market Drivers and Limiters
Exhibit ES-8: Neurostimulation Products (Including Cochlear Implants), Market Forecast, 2005-2010
Exhibit ES-9: 2005, Neurostimulation Products Market, Estimated Percentage of Sales, by Application
Exhibit ES-10: Neurostimulation Products (Excluding Cochlear Implants), Market Forecast, 2005-2010
Exhibit ES-11: Transcutaneous Electrical Nerve Stimulators, Market Forecast, 2005-2010
1. OVERVIEW OF THE NERVOUS SYSTEM AND ITS DISORDERS
1.1 The Nervous System
1.1.1 Sacral Nerves
1.1.2 Vagus Nerve
1.1.3 Neurons
1.1.4 Brain
1.1.5 Spine
1.2 Neurologic and Other Diseases/Disorders
1.2.1 Alzheimer's Disease
1.2.1.1 Etiology
1.2.1.2 Incidence
1.2.1.3 Prevalence
1.2.1.4 Treatment Options
1.2.1.4.1 Drug Therapy
1.2.1.4.2 Neurostimulation and Other Device-Based Therapy
1.2.1.4.3 Surgery
1.2.1.4.4 Prevention
1.2.2 Depression
1.2.2.1 Etiology
1.2.2.2 Incidence
1.2.2.3 Prevalence
1.2.2.4 Treatment Options
1.2.2.4.1 Drug Therapy
1.2.2.4.2 Neurostimulation
1.2.2.5 Prevention
1.2.3 Epilepsy
1.2.3.1 Etiology
1.2.3.2 Incidence
1.2.3.3 Prevalence
1.2.3.4 Treatment Options
1.2.3.4.1 Drug Therapy
1.2.3.4.2 Neurostimulation
1.2.3.4.3 Surgery
1.2.3.4.4 Prevention
1.2.4 Gastroparesis
1.2.4.1 Etiology
1.2.4.2 Incidence
1.2.4.3 Prevalence
1.2.4.4 Treatment Options
1.2.4.4.1 Drug Therapy
1.2.4.4.2 Neurostimulation
1.2.4.4.3 Surgery
1.2.4.4.4 Prevention
1.2.5 Obesity
1.2.5.1 Etiology
1.2.5.2 Incidence
1.2.5.3 Prevalence
1.2.5.4 Treatment Options
1.2.5.4.1 Drug Therapy
1.2.5.4.2 Neurostimulation
1.2.5.4.3 Surgery
1.2.5.4.4 Prevention
1.2.6 Incontinence
1.2.6.1 Etiology
1.2.6.2 Incidence
1.2.6.3 Prevalence
1.2.6.4 Treatment Options
1.2.6.4.1 Drug Therapy
1.2.6.4.2 Neurostimulation
1.2.6.4.3 Surgery
1.2.6.4.4 Prevention
1.2.7 Pain
1.2.7.1 Nociceptive Pain
1.2.7.2 Neuropathic Pain
1.2.7.3 Acute Pain
1.2.7.4 Chronic Pain
1.2.7.4.1 Etiology
1.2.7.4.2 Incidence
1.2.7.4.3 Prevalence
1.2.7.4.4 Treatment Options
1.2.7.4.4.1 Drug Therapy
1.2.7.4.4.2 Neurostimulation and Other Device-Based Therapy
1.2.7.4.4.3 Alternative Therapy
1.2.7.4.5 Chronic Migraine
1.2.7.4.5.1 Neurostimulation
1.2.8 Parkinson's Disease
1.2.8.1 Etiology
1.2.8.2 Incidence
1.2.8.3 Prevalence
1.2.8.4 Treatment Options
1.2.8.4.1 Drug Therapy
1.2.8.4.2 Neurostimulation
1.2.8.4.3 Surgery
1.2.8.4.4 Prevention
1.2.9 Essential Tremor
1.2.9.1 Etiology
1.2.9.2 Incidence
1.2.9.3 Prevalence
1.2.9.4 Treatment Options
1.2.9.4.1 Drug Therapy
1.2.9.4.2 Neurostimulation
1.2.9.4.3 Surgery
1.2.9.4.4 Prevention
1.2.10 Stroke
1.2.10.1 Etiology
1.2.10.2 Incidence
1.2.10.3 Prevalence
1.2.10.4 Treatment Options
1.2.10.4.1 Drug Therapy
1.2.10.4.2 Neurostimulation and Other Device-Based Therapy
1.2.10.4.3 Surgery
1.2.10.4.4 Prevention
Exhibit 1-1: 2006, Selected Neurologic Conditions, Estimated Prevalence and Potential Neurostimulation Patient Population
Exhibit 1-2: The Vagus Nerve
Exhibit 1-3: 2005, Alzheimer's Disease, Facts and Figures
Exhibit 1-4: 2005, Depression, Facts and Figures
Exhibit 1-5: 2005, Epilepsy, Facts and Figures
Exhibit 1-6: 2005, Gastroparesis, Facts and Figures
Exhibit 1-7: 2005, Obesity, Facts and Figures
Exhibit 1-8: 2005, Urinary Incontinence, Facts and Figures
Exhibit 1-9: Common Causes of Neuropathic Pain
Exhibit 1-10: 2005, Acute Pain, Facts and Figures
Exhibit 1-11: 2005, Chronic Pain, Facts and Figures
Exhibit 1-12: 2005, Migraine Headache, Facts and Figures
Exhibit 1-13: 2005, Parkinson's Disease, Facts and Figures
Exhibit 1-14: 2005, Essential Tremor, Facts and Figures
Exhibit 1-15: 2005, Stroke, Facts and Figures
2. NEUROSTIMULATION PRODUCTS MARKET
2.1 Background
2.2 Types of Implantable Neurostimulators
2.2.1 Cortical Stimulators
2.2.2 Deep Brain Stimulators
2.2.3 Gastric Nerve Stimulators
2.2.4 Sacral Nerve Stimulators
2.2.5 Spinal Cord Stimulators
2.2.6 Vagus Nerve Stimulators
2.2.7 Cochlear Implants
2.3 Core Treatment Areas
2.3.1 Major Depression
2.3.1.1 Advanced Neuromodulation Systems/St. Jude Medical
2.3.1.2 Cyberonics
2.3.1.3 Medtronic
2.3.1.4 Northstar Neuroscience
2.3.2 Epilepsy
2.3.2.1 Cyberonics
2.3.2.2 Medtronic
2.3.2.3 NeuroPace
2.3.3 Gastroparesis
2.3.3.1 Medtronic
2.3.4 Hearing Loss
2.3.4.1 Advanced Bionics/Boston Scientific
2.3.4.2 Cochlear
2.3.4.3 MED-EL Medical Electronics
2.3.5 Incontinence
2.3.5.1 Advanced Bionics/Boston Scientific
2.3.5.2 Neopraxis Pty. Limited/Cochlear
2.3.5.3 Medtronic
2.3.5.4 NDI Medical
2.3.5.5 Victhom Human Bionics
2.3.6 Pain
2.3.6.1 Advanced Bionics/Boston Scientific
2.3.6.2 Advanced Neuromodulation Systems/St. Jude Medical
2.3.6.3 Medtronic
2.3.7 Parkinson's Disease, Dystonia, and Essential Tremor
2.3.7.1 Advanced Neuromodulation Systems/St. Jude Medical
2.3.7.2 Medtrode
2.3.7.3 Medtronic
2.3.7.3.1 Parkinson's Disease
2.3.7.3.2 Essential Tremor
2.3.7.3.3 Dystonia
2.3.8 Sleep Apnea
2.3.8.1 Avery Biomedical Devices
2.3.8.2 NDI Medical
2.4 Emerging Applications
2.4.1 Alzheimer's Disease
2.4.1.1 Cyberonics
2.4.2 Blindness
2.4.2.1 Second Sight
2.4.3 Chronic Headache
2.4.3.1 Advanced Bionics/Boston Scientific
2.4.3.2 Advanced Neuromodulation Systems/St. Jude Medical
2.4.3.3 Medtronic
2.4.4 Chronic Heart Failure
2.4.4.1 Impulse Dynamics
2.4.5 Obesity
2.4.5.1 Advanced Neuromodulation Systems/St. Jude Medical
2.4.5.2 Cyberonics
2.4.5.3 EnteroMedics
2.4.5.4 GI Dynamics
2.4.5.5 IntraPace
2.4.5.6 Leptos Biomedical
2.4.5.7 Medtronic
2.4.5.8 MetaCure
2.4.6 Stroke
2.4.6.1 Northstar Neuroscience
2.4.7 Paralysis/Spinal Cord Injury
2.4.7.1 Andara Life Science/Cyberkinetics Neurotechnology Systems
2.4.7.2 Ossur/Victhom Human Bionics
2.4.8 Tinnitus
2.4.8.1 NeuroSystec
2.4.9 Other Emerging Neurostimulation Companies
2.5 Nonsurgical/Noninvasive Stimulation
2.5.1 Magnetic Nerve Stimulation
2.5.1.1 Magstim
2.5.1.2 Moeller Medical
2.5.1.3 Neotonus
2.5.1.4 Neuronetics
2.5.1.5 Nexstim
2.5.2 Transcutaneous Electrical Nerve Stimulators and Electrotherapy Products
2.5.2.1 American Imex
2.5.2.2 BioMedical Life Systems
2.5.2.3 Compex Technologies/Encore Medical
2.5.2.4 Cyclotec AMT
2.5.2.5 Dynatronics
2.5.2.6 Empi/Encore Medical
2.5.2.7 RS Medical
2.5.2.8 Zynex Medical
2.6 Other Noninvasive Electrical Stimulation Technologies
2.6.1 Innovative Neurotronics/Hanger Orthopedic Group
2.6.2 Zynex Medical
2.7 Market Analysis
2.8 Competitive Analysis
Exhibit 2-1: 2006, Selected Advantages and Disadvantages of Neurostimulation Therapy
Exhibit 2-2: 2006, Neurostimulation, Potential Applications
Exhibit 2-3: 2006, Patients Who Have Received Neurostimulation Implants, by Selected Neurologic Condition
Exhibit 2-4: 2006, Selected Neurologic Conditions, Estimated Prevalence and Potential Neurostimulation Patient Population
Exhibit 2-5: 2006, Established Neurostimulation Therapies and Leading Competitors
Exhibit 2-6: 2006, Selected Current and Emerging Neurostimulation Systems
Exhibit 2-7: Neurostimulation in Suppressing Epileptic Seizures, NeuroPace's Responsive Neurostimulator Therapy
Exhibit 2-8: Neurostimulation in the Treatment of Gastroparesis, Medtronic's Enterra Therapy
Exhibit 2-9: Advanced Bionic's Cochlear Implant
Exhibit 2-10: Cochlear's Nucleus Freedom Implant
Exhibit 2-11: Medtronic's InterStim Therapy System
Exhibit 2-12: Medtronic's Neurostimulators for Treating Chronic Pain
Exhibit 2-13: Medtronic's RESTOREPRIME and Restore Therapy System
Exhibit 2-14: Medtronic's Activa Therapy for Parkinson's Disease and Essential Tremor
Exhibit 2-15: Second Sight's Intraocular Retinal Prosthesis
Exhibit 2-16: Northstar Neuroscience's Stroke Recovery System
Exhibit 2-17: 2006, Selected Magnetic Stimulation Systems
Exhibit 2-18: Magstim's Magnetic Nerve Stimulation Technology
Exhibit 2-19: 2006, Selected Conditions That May Be Treated Using Transcutaneous Electrical Nerve Stimulation
Exhibit 2-20: 2006, Selected Transcutaneous Electrical Nerve Stimulation Devices
Exhibit 2-21: Compex Technologies, Selected Transcutaneous Electrical Nerve Stimulation Devices
Exhibit 2-22: Cyclotec AMT's Miniature CT1 Transcutaneous Electrical Nerve Stimulation Device
Exhibit 2-23: Dynatronic's Sympathetic Therapy System
Exhibit 2-24: Empi's Infinity Plus Transcutaneous Electrical Nerve Stimulation System
Exhibit 2-25: Zynex Medical's TruWave and Elpha 1000 Transcutaneous Electrical Nerve Stimulation Systems
Exhibit 2-26: Innovative Neurotronics' WalkAide
Exhibit 2-27: 2006, Selected Market Drivers and Limiters
Exhibit 2-28: Neurostimulation Products (Including Cochlear Implants), Market Forecast, 2005-2010
Exhibit 2-29: 2005, Neurostimulation Products Market, Estimated Percentage of Sales, by Application
Exhibit 2-30: Neurostimulation Products (Excluding Cochlear Implants), Market Forecast, 2005-2010
Exhibit 2-31: Transcutaneous Electrical Nerve Stimulators, Market Forecast, 2005-2010
Exhibit 2-32: 2005, Neurostimulation Products Market (Excluding Cochlear Implants), Share by Supplier
Exhibit 2-33: 2005, Neurostimulation Products Market (Including Cochlear Implants), Share by Supplier
Exhibit 2-34: 2005, Cochlear Implant Products Market, Share by Supplier
Exhibit 2-35: 2005, Transcutaneous Electrical Nerve Stimulators Market, Share by Supplier
3. COMPANY PROFILES
3.1 Advanced Bionics Corporation/Boston Scientific Corporation
3.2 Advanced Neuromodulation Systems, Inc./St. Jude Medical, Inc.
3.3 Andara Life Science, Inc./Cyberkinetics Neurotechnology Systems, Inc.
3.4 Cochlear LTD
3.5 Compex Technologies, Inc./Encore Medical Corporation
3.6 Cyberonics, Inc.
3.7 Dynatronics Corporation
3.8 EnteroMedics, Inc.
3.9 Impulse Dynamics NV
3.10 IntraPace, Inc.
3.11 Leptos Biomedical, Inc.
3.12 Magstim Company LTD
3.13 Medtronic, Inc.
3.14 MetaCure NV
3.15 NDI Medical LLC
3.16 Neotonus, Inc.
3.17 Neuronetics, Inc.
3.18 NeuroPace, Inc.
3.19 NeuroSystec Corporation
3.20 Nexstim LTD
3.21 Northstar Neuroscience, Inc.
3.22 Second Sight, Inc.
3.23 Victhom Human Bionics, Inc.
- Advanced Bionics Corporation/Boston Scientific Corporation
- Advanced Neuromodulation Systems, Inc./St. Jude Medical, Inc.
- Andara Life Science, Inc./Cyberkinetics Neurotechnology Systems, Inc.
- Cochlear LTD
- Compex Technologies, Inc./Encore Medical Corporation
- Cyberonics, Inc.
- Dynatronics Corporation
- EnteroMedics, Inc.
- Impulse Dynamics NV
- IntraPace, Inc.
- Leptos Biomedical, Inc.
- Magstim Company LTD
- Medtronic, Inc.
- MetaCure NV
- NDI Medical LLC
- Neotonus, Inc
- . Neuronetics, Inc.
- NeuroPace, Inc.
- NeuroSystec Corporation
- Nexstim LTD
- Northstar Neuroscience, Inc.
- Second Sight, Inc.
- Victhom Human Bionics, Inc.
Request Sample
A Single License allows for one person to access the report. A Corporate License allows for multiple individuals within a company to access the report.